195 related articles for article (PubMed ID: 38555869)
1. Current and future genomic applications for surgeons.
Alkhatib O; Miles T; Jones RP; Mair R; Palmer R; Winter H; McDermott FD
Ann R Coll Surg Engl; 2024 Apr; 106(4):321-328. PubMed ID: 38555869
[TBL] [Abstract][Full Text] [Related]
2. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
3. Implications for the colorectal surgeon following the 100 000 Genomes Project.
McDermott FD; Newton K; Beggs AD; Clark SK
Colorectal Dis; 2021 May; 23(5):1049-1058. PubMed ID: 33471415
[TBL] [Abstract][Full Text] [Related]
4. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
8. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill HR
Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
11. Development of circulating tumour DNA analysis for gastrointestinal cancers.
Nakamura Y; Shitara K
ESMO Open; 2020 Jan; 5(Suppl 1):e000600. PubMed ID: 32830648
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
Venesio T; Siravegna G; Bardelli A; Sapino A
Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
[TBL] [Abstract][Full Text] [Related]
14. The value of cell-free DNA for molecular pathology.
Stewart CM; Kothari PD; Mouliere F; Mair R; Somnay S; Benayed R; Zehir A; Weigelt B; Dawson SJ; Arcila ME; Berger MF; Tsui DW
J Pathol; 2018 Apr; 244(5):616-627. PubMed ID: 29380875
[TBL] [Abstract][Full Text] [Related]
15. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
17. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R; Xu Q; Guo H; Yang G; Zhang J; Wang H; Xu T; Guo C; Yuan J; He Y; Zhang X; Fu H; Xu G; Zhao B; Xie J; Zhao T; Huang L; Zhang J; Peng B; Yao X; Yang B
Cancer Res Commun; 2023 Nov; 3(11):2221-2232. PubMed ID: 37877742
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
19. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.
Helal C; Pobel C; Bayle A; Vasseur D; Nicotra C; Blanc-Durand F; Naoun N; Bernard-Tessier A; Patrikidou A; Colomba E; Flippot R; Fuerea A; Auger N; Ngo Camus M; Besse B; Lacroix L; Rouleau E; Ponce S; Italiano A; Loriot Y
Eur J Cancer; 2023 Dec; 195():113368. PubMed ID: 37897866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]